Introduction
============

As antibody-based therapeutics, full-length monoclonal antibodies have little competition so far.[@R1]^-^[@R3] In fact, most approved monoclonal antibodies and those in regulatory review are canonical IgG antibodies ([www.landesbioscience.com/journals/mabs/about/](http://www.landesbioscience.com/journals/mabs/about/)). The disadvantages of these molecules, such as costly and time-consuming production in mammalian cell lines, large (\~150 kDa) and complex molecular structures, poor tissue penetration and inability to access cryptic epitopes, and the fact that the Fc portion of the antibody is not needed in many instances or may even be harmful, have resulted in the creation of a niche that can be occupied by antibody fragments.[@R2]^,^[@R4]^,^[@R5] These smaller antibody fragments, including single-domain antibodies (sdAbs), have unique features that may make them the preferred therapeutic format for many applications. Currently, there are numerous antibody fragments in clinical development, with some being sdAbs.[@R2]^,^[@R4]

sdAbs, e.g., human V~H~s, human V~L~s, camelid V~H~Hs, have become a viable option in the antibody-based therapeutic tool box that also includes IgGs, antigen-binding fragments (Fabs), single chain Fv fragments (scFvs), and their many derivatives. Appealing features of sdAbs include their high affinity (nM - pM equilibrium dissociation constant (*K*~D~) range) for cognate antigens,[@R6]^-^[@R29] small size (\~15 kDa) and simple structure, single domain nature, modularity, low immunogenicity, high-level expression in microorganisms such as bacteria, high thermal, chemical and protease stabilities, high solubility and aggregation resistance, ability to access cryptic epitopes, and ease of genetic manipulation and display library construction.[@R5]^,^[@R30]^,^[@R31] V~H~Hs are more convenient to obtain due to their better biophysical properties and the existence and accessibility of in vivo naïve and immune V~H~H repertoire sources, but human V~H~s and V~L~s have the perceived advantage of being less immunogenic in human therapy. A number of reports have implied human V~L~s may be superior therapeutic candidates compared with human V~H~s because of their lower tendency to aggregate,[@R32]^-^[@R34] which may translate to lower immunogenicity and in turn higher therapeutic efficacy for V~L~s.

In vivo, human V~L~ constructs are the result of genetic recombination between germline gene segments V~L~ and J~L~. The first two complementarity-determining regions (CDR1 and CDR2) and a part of the CDR3 up to residue 95 are encoded by V~L~ segment genes; the rest of the CDR3 and the entire framework region (FR) 4 are encoded by J~L~ gene segments.[@R35] Human V~L~s are classified as either κ or λ subtypes, with seven V~κ~ gene segment subgroups (V~κ~1--7) within the κ class and 11 V~λ~ gene segment subgroups (V~λ~1--11) within the λ class (<http://www.imgt.org/>).[@R36]^,^[@R37] In general, V~κ~ domains exhibit higher solubility and stability than V~λ~ domains, possibly due to a higher packing density in their upper core and a more hydrophilic C-terminus, and among the V~κ~ subgroups, V~κ~3 subgroup members exhibit the best properties in terms of solubility and thermodynamic stability.[@R33]^,^[@R38] A significant proportion of human V~L~s, predominantly of V~κ~ class, bind to the B cell super-antigen protein L.[@R39]^-^[@R41]

V~L~ domains are similar to V~H~s in terms of overall structure. They are composed of two β-sheets that are formed by several anti-parallel β-strands and pack face-to-face to form β-sandwich structures.[@R42] Also, similar to V~H~s, they possess a pair of cysteine residues at spatially equivalent positions (Kabat positions 23 and 88)[@R43] that form a highly conserved disulfide linkage. This linkage, which pins together the two β-sheets in the core of V~L~ domains, plays a critical role in maintaining the structural integrity of V~L~s.[@R44]^,^[@R45] Previously, it was shown that engineering an additional disulfide linkage in the core of a set of human V~H~s improved their aggregation resistance and thermostability.[@R46]^,^[@R47] Given the overall structural similarity between V~H~ and V~L~s, it is hypothesized that the same engineering approach, with similar stability improvements, should be applicable to V~L~s.

Here, to further explore the merits of human V~L~s as therapeutic modalities, we set out to perform an extensive biophysical characterization of a set of test V~L~s. We constructed a naïve human V~L~ phage display library, and from it isolated a diversity of domains with protein L binding property by a phage selection method that was previously shown to be highly selective for non-aggregating human V~H~ domains.[@R48] We then characterized a representative sample of V~L~s for properties such as expression yield, non-aggregation, thermal stability, reversible thermal unfolding, structural integrity, and protease resistance. Next, we determined if a non-canonical disulfide linkage engineering approach previously shown to improve the thermostability and protease resistance of camelid V~H~Hs and human V~H~s[@R46]^,^[@R47]^,^[@R49]^-^[@R52] would do the same for the present V~L~s. Thus, we engineered human V~L~s with an additional, non-canonical disulfide linkage between Cys48 and Cys64 in β-strands C' and D. We then performed pair-wise biophysical comparisons between wild-type and their corresponding Cys mutant domains.

Results
=======

Identification and sequence analysis of human V~L~s
---------------------------------------------------

Essentially the same selection method employed to isolate non-aggregating V~H~s from a human V~H~ phage display library was applied to a human V~L~ library for isolating soluble, monomeric V~L~s.[@R48] A human V~L~ library with a size of 3 × 10^6^ transformants was constructed. Twenty-four clones (plaques) from the library titer plates were isolated and their V~L~ genes were amplified by PCR and then sequenced. The sequences were diverse in terms of germ-line origin, although 75% of the V~L~s were of V~λ~ origin (data not shown). Three rounds of panning against protein L resulted in enrichment for large plaques. Thirty-four of the large plaques were sequenced and 32 unique sequences were identified ([Fig. 1](#F1){ref-type="fig"}). Except for HVLP389, which is from the λ class (subgroup V~λ~1, V germline 1b), the remaining 31 V~L~s belonged to the V~κ~ class. Of the 31 κ class V~L~s, 24 fell within the V~κ~3 subgroup and 7 fell within the V~κ~1 subgroup. Sixteen of the 24 V~κ~3 sequences utilized the L6 V germline sequence, while the remaining sequences utilized A27, L2, and L16 V germline sequences. The V~κ~1 subgroup V~L~s originated from the O2/O12 or A30 V germline sequence. Noticeable mutations occurred at position 96. The germline amino acids at this position are aromatic and hydrophobic amino acids Trp, Phe, Tyr, Leu or Ile for κ class V~L~s, and Tyr, Val or Ala for λ class V~L~s. In the selected pool of κ class V~L~s, however, only 5 out of 31 V~L~s had their germline amino acids at position 96: HVLP325, HVLP349, HVLP388, HVLP3109, and HVLP393; 21 V~L~s had charged amino acids, of which 20 were positively charged, 2 had Pro, 1 had Gln, 1 had Ser, and one had Thr at positions 96. Moreover, 18 V~L~s of the κ class had their last three germline residues (105--107) replaced with amino acids Thr, Val, and Leu, which are only found in λ class V~L~s.

![**Figure 1.** Amino acid sequences of V~L~s selected from a human V~L~ phage display library by panning against protein L. The dots in the sequence entries indicate amino acid identity with HVLP333. Dashes are included for sequence alignment. See *V BASE* (<http://vbase.mrc-cpe.cam.ac.uk/index.php?&MMN_position=1:1>) for sequence numbering and CDR and FR designations. L6, A27, L2, L16, O2/O12, A30, and 1b are V germline gene segment designations. J germline gene segment designations are in brackets. NF, not found.](mabs-6-219-g1){#F1}

Expression yield and aggregation status of human V~L~s
------------------------------------------------------

Eight of the selected V~L~s representing different V germline origins were expressed in *E. coli* TG1 in 1 L cultures and purified: HVLP324, HVLP325, HVLP335, HVLP342, HVLP351, HVLP364, HVLP389 and HVLP3103 ([Fig. 2A](#F2){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). All were expressed in good yields ranging from 6.2 mg for HVLP325 to \~75 mg for HVLP335 and HVLP364. The aggregation tendency of the human V~L~s was assessed by Superdex 75™ size-exclusion chromatography (SEC).[@R47] At a concentration of 0.6 mg/mL (43 µM) all V~L~s were essentially free of aggregates and gave single, symmetrical peaks ([Fig. 3A](#F3){ref-type="fig"}). HVLP351, HVLP342, HVLP335 and HVLP3103, were still monomers when tested at their highest concentration available, i.e., 0.89 mg/mL (64 µM), 1.0 mg/mL (72 µM), 4.9 mg/mL (352 µM), and 5.9 mg/mL (430 µM), respectively, although slight tailing was observed for the HVLP335 monomeric peak at 5.9 mg/mL, suggesting V~L~ interaction with the column matrix. The apparent molecular masses (*M*~app~s) of V~L~s, calculated from their elution volumes ([Fig. S1](#SUP1){ref-type="supplementary-material"}), ranged from 6.9 kDa to 24.3 kDa, with a mean *M*~app~ ± SEM of 13.7 ± 2.2 kDa and a *M*~for~ ± SEM of 13.8 ± 0.04 kDa. Variation in *M*~app~s for non-aggregating V~L~s with similar formula molecular masses (*M*~for~s) has been reported previously.[@R32] Such variation was also observed in the case of highly non-aggregating V~H~s and may have been the result of weak transient interactions with the column materials or monomer/dimer equilibria.[@R53] The non-aggregating status of V~L~s was confirmed by a surface plasmon resonance (SPR) assay based on the Ni^2+^-His~6~ tag interaction that involved flowing His-tagged V~L~s over Ni^2+^-immobilized sensorchip surfaces.[@R46] Similar to previous results obtained with monomeric V~H~s, for the two dissociation phase windows tested, all the C-terminally His~6~-tagged V~L~s gave *k*~off~s that are very similar to those of the monomeric V~H~H control, but drastically faster than those for the dimeric V~H~ control with two C-terminal His~6~ tags, confirming the monomeric status of the V~L~s ([Fig. 3B](#F3){ref-type="fig"}). This conclusion was accurately endorsed by the multiangle light scattering (MALS) experiments, which showed that the V~L~s had *M*~MALS~s (molecular masses determined by MALS) that were very similar to their *M*~for~s ([Table 1](#T1){ref-type="table"}).

![**Figure 2.** Structure of a set of human V~L~s chosen for detailed biophysical analyses. (**A**) Amino acid sequences of eight human V~L~s and their Cys mutant versions. The amino acid positions (48 and 64) where mutations to cysteine residues were made are marked. (**B**) Homology structures of wild-type (left) and Cys mutant (right) of HVLP324. The native and engineered non-canonical disulfide linkages are shown as green and red spheres, respectively. Protein homology structures were obtained using the Geno3D automatic modeling tool (<http://pbil.ibcp.fr/htm/index.php>). The figures were drawn with PyMOL (<http://www.pymol.org>) and Disulfide by Design (version 1.20) freeware.[@R80]](mabs-6-219-g2){#F2}

###### **Table 1.** Biophysical characteristics of V~L~s

  V~L~              Subgroup   *M*~for~ (kDa)   *M*~MALS~ (kDa)^a^   Expression yield (mg)^b^   *K*~D~ (µM)    V~L~:protein L^c^   *T~m~* (°C)   Δ*T~m~* (°C)   TRE (%)^d^   GI protease resistance (%)^e^               
  ----------------- ---------- ---------------- -------------------- -------------------------- -------------- ------------------- ------------- -------------- ------------ ------------------------------- ----- ----- ----
  **HVLP324**       V~κ~1      13.83            13.84 ± 0.76         2.5, 7                     0.2, 0.07^f^   7:1                 66.1          7.3            90           78                              34    100   22
  **HVLP324S**      13.87      14.68 ± 0.58     0.5, 1.1             0.1, 0.06^f^               7:1            73.4                ND^g^         ND^g^          32           36                              46          
  **HVLP325**       V~κ~3      13.61            13.5 ± 0.63          0.5, 6.2                   1              3:1                 68.5          14             94           65                              67    76    34
  **HVLP325S**      13.66      13.35 ± 0.64     2.2, 3.1             1                          3:1            82.5                ND^g^         ND^g^          81           93                              100         
  **HVLP335**       V~κ~3      13.90            15.26 ± 0.50         73.5                       2              3:1                 61.7          17.3           92           95                              2     59    0
  **HVLP335S**      13.94      16.8 ± 0.47      5.5                  2                          3:1            79.0                ND^g^         ND^g^          0            32                              62          
  **HVLP342**       V~κ~1      13.95            14.22 ± 0.64         1, 7.7                     0.6, 0.04^f^   7:1                 58.4          5.4            92           70                              25    73    3
  **HVLP342S**      13.99      17.02 ± 0.40     1.7, 10.8            0.2, 0.05^f^               7:1            63.8                ND^g^         ND^g^          5            40                              5           
  **HVLP351**       V~κ~3      13.85            14.60 ± 0.61         1.2, 8.9                   2              2:1                 62.0          9.9            87           65                              71    100   31
  **HVLP351S**      13.89      14.61 ± 0.53     1.9, 4.8             0.7                        2:1            71.9                ND^g^         ND^g^          100          99                              94          
  **HVLP364**       V~κ~3      13.95            14.20 ± 0.58         0.3, 77                    3              3:1                 57.0          15.3           100          92                              32    58    0
  **HVLP364S^h^**   13.97      14.98 ± 0.43     4.7                  ND^g^                      ND^g^          72.3                ND^g^         ND^g^          0            12                              0           
  **HVLP3103**      V~κ~3      13.85            14.29 ± 0.64         0.7, 19                    1              3:1                 65.7          10.7           94           92                              81    90    0
  **HVLP3103S**     13.89      14.05 ± 0.68     6.5                  1                          3:1            76.4                ND^g^         ND^g^          47           80                              89          
  **HVLP389**       V~λ~1      13.69            15.12 ± 0.50         3, 16.7                    1              1:1                 51.9          14.4           91           91                              15    74    0
  **HVLP389S**      13.72      13.65 ± 0.68     6.5                  1                          1:1            66.3                ND^g^         ND^g^          64           90                              11          

^a^ Mean ± SEM; ^b^Expression yield values are per liter of bacterial culture. Two expression yield values correspond to two independent expression trials; ^c^Stoichiometry of V~L~-protein L binding; ^d^Thermal refolding efficiency at 4 and 20 µM V~L~ concentrations, respectively; ^e^Percentage proteolytic resistance values are at protease concentrations of 10 µg/mL (see also [Fig. 6E](#F6){ref-type="fig"}); ^f^Smaller *K*~D~ values correspond to the binding of HVLP324, HVLP324S, HVLP342, and HVLP342S to the high affinity sites on protein L; ^g^ND, not determined; ^h^HVLP364S additionally gave a significant second peak ([Fig. 3A](#F3){ref-type="fig"}) with a smaller elusion volume and a *M*~MALS~ of 26.21 ± 0.47 kDa.

![**Figure 3.** Size-exclusion chromatography and SPR analyses of wild-type and mutant V~L~s. (**A**) Superdex 75™ size-exclusion chromatograms of V~L~s with monomeric peaks marked with arrowheads. For HVLP364S, the dimeric V~L~ peak situated to the left of the monomeric peak is visible. (**B**) SPR analysis of V~L~ binding to a Ni^2+^-NTA sensorchip. A llama V~H~H Monomer (A4.2[@R49]) and a V~H~ Dimer[@R81] were used as controls. Measurements were taken at two dissociation phase windows (315--375 s and 780--840 s) and the mean values obtained from two independent trials performed in duplicates were recorded in the table. SPR experiments were performed with SEC-purified V~L~s.](mabs-6-219-g3){#F3}

Protein L binding of human V~L~s
--------------------------------

As anticipated, all selected V~L~s bound to protein L in SPR analysis ([Fig. S2A](#SUP1){ref-type="supplementary-material"}; [Table 1](#T1){ref-type="table"}). The *K*~D~s of binding to protein L were in the 0.2--3 µM range, with HVLP324 and HVLP342, which belong to V~κ~1 subgroup, showing additional smaller *K*~D~s of 0.07 µM and 0.04 µM, respectively, when Biacore analyses were performed at a low concentration range (1--10 nM) ([Table 1](#T1){ref-type="table"}). The estimated stoichiometry of binding, V~L~:protein L, were 7 for V~κ~1 subgroup members, 3 for all V~κ~3 subgroup members except for HVLP351 which was 2, and 1 for HVLP389, a V~λ~1 member.

*T*~m~s of human V~L~s
----------------------

To assess the thermostability of the V~L~s, *T*~m~s of V~L~s were determined based on ellipticity data assuming a two-state system, which is in agreement with the observed denaturation curves corresponding to a sharp transition into denaturation ([Fig. 4A](#F4){ref-type="fig"}). *T*~m~s, taken at midpoint of the sigmoidal denaturation curves of molar ellipticity change (Δθ) vs. temperature (°C), were in the range of 51.9--68.5 °C (median *T*~m~ = 61.9°C) ([Table 1](#T1){ref-type="table"}). The lowest *T*~m~ was that of HVLP389, which is the only V~L~ of λ family among the eight V~L~s, and the highest *T*~m~ was that of HVLP325, which showed slight aggregation ([Fig. 3A](#F3){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). The *T*~m~s of eight non-aggregating V~H~s (HVHP428, HVHP413, HVHP414, HVHP421, HVHP429, HVHP44, HVHP420, and HVHP419) isolated previously in the same manner as V~L~s[@R48] were also determined for comparison. The *T*~m~ range was 54.2--64.2 °C and the median *T*~m~ was 57.6°C; the *T*~m~ differences between V~L~s and V~H~s were not significant (Mann-Whitney test, two-tailed;*P*= 0.2345) ([Fig. 4B and D](#F4){ref-type="fig"}).

![**Figure 4.** Thermostability analysis of antibody domains. Thermal unfolding curves of (**A**) wild-type V~L~s, (**B)** V~H~s, and (**C**) mutant V~L~s. *T*~m~s were calculated and incorporated into [Figure 4D](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}. The non-aggregating V~H~s are described in ref. [@R48]. (**D**) Graph comparing the *T*~m~s of wild-type V~L~s to those of V~H~s and mutant V~L~s.](mabs-6-219-g4){#F4}

Thermal refolding efficiency of human V~L~s
-------------------------------------------

The ability of the human V~L~s to refold following thermal denaturation was assessed by determining their thermal refolding efficiencies (TREs), which is calculated as the ratio of the *K*~D~s for the binding of the native V~L~s to protein L (*K*~D~n) to the *K*~D~s for the binding of the heat-denatured/cooled (refolded) V~L~s to protein L (*K*~D~ref).[@R48]^,^[@R54] *K*~D~s were determined by SPR ([Fig. 5](#F5){ref-type="fig"}; [Fig. S3](#SUP1){ref-type="supplementary-material"}; [Table 1](#T1){ref-type="table"}). [Figures 5A and B](#F5){ref-type="fig"} compare the protein L binding sensorgram profiles for HVLP335 and HVLP325, respectively, in native and refolded states at 20 µM V~L~ concentrations. It can be seen that for HVLP335, with near perfect refolding (95%) ([Table 1](#T1){ref-type="table"}), the sensorgrams for the native and refolded species are almost superimposable. In contrast, for HVLP325 with 65% TRE ([Table 1](#T1){ref-type="table"}), a significant drop in binding is observed for refolded species compared with the native species when sensorgrams at the same concentrations are compared. At 4 µM V~L~ concentrations, TREs are in the range of 90--100%, except for HVLP351, which is slightly lower at 87%, indicating a near perfect refolding for V~L~s (median = 92%) ([Fig. 5C](#F5){ref-type="fig"}). At 20 µM V~L~ concentrations, the TREs significantly decrease, with V~L~s having a TRE range of 65--95% and a TRE median dropping to 84.5% (Wilcoxon matched-pairs signed rank test, two-tailed;*P*= 0.0469) ([Fig. 5C](#F5){ref-type="fig"}). However, for four V~L~s (HVLP335, HVLP364, HVLP389, HVLP3103), TRE values still remains above 90%, and for three of the four, TREs do not change when V~L~ concentrations are increased from 4 µM to 20 µM. For comparison, the TREs of the eight non-aggregating V~H~s at 4 µM and 20 µM V~H~ concentrations are also included ([Fig. 5C](#F5){ref-type="fig"}; [Fig. S4](#SUP1){ref-type="supplementary-material"}). Two of the eight V~H~s (HVHP428 and HVHP413) showed low TREs of 48% and 7% at 4 µM, with the remaining 6 V~H~s (HVHP414, HVHP421, HVHP429, HVHM44, HVHP420, HVHP419) having TREs of 90--98% (median = 92%). As with V~L~s, the TREs of V~H~s at 20 µM concentrations decreased significantly (median = 78.5%, Wilcoxon matched-pairs signed rank test, two-tailed;*P*= 0.0078), with HVHP428 and HVHP413 V~H~s failing to refold (TRE = 2% and 1%, respectively). Statistical analysis of TREs revealed that V~L~s were comparable to V~H~s in terms of reversibility of thermal unfolding (Mann-Whitney test, two-tailed;*P*= 0.8785 \[4 µM\],*P*= 0.5054 \[20 µM\]). Moreover, the drops in TRE values as a function of increased concentrations of V~H~s and V~L~s are significant and expected as previously reported.[@R55] No significant correlation between TRE and *T*~m~ was found.

![**Figure 5.** Thermal refolding efficiency determination of human V~L~s and V~H~s by SPR. (**A**), (**B**) Representative SPR sensorgrams for the binding of native and heat-denatured/cooled (refolded) human V~L~s to immobilized protein L. Data are from TRE experiments performed at 20 µM V~L~ concentrations. V~L~ concentrations used to construct each sensorgram set was 12.5, 18.8, 25, 37.5, 50, 75, and 100 nM for HVLP325 and 12.5, 20, 25, 30, 38, 50, and 75 nM for HVLP335. See [Figure S3 and S4](#SUP1){ref-type="supplementary-material"} for SPR data for all V~L~s and V~H~s. The *K*~D~ns and *K*~D~refs determined from "Native" and "Refolded" sensorgram pairs were used to determine TREs in (**C**). (**C**) TREs of wild-type V~L~s and V~H~s obtained under 4 µM and 20 µM domain concentration conditions in refolding experiments. Lines connect TREs for the same clones.](mabs-6-219-g5){#F5}

Protease resistance of human V~L~s
----------------------------------

In addition to thermostability, e.g., *T*~m~, protease resistance is also a measure of protein stability. To determine protease resistance, V~L~s were treated with major gastrointestinal **(**GI) proteases, trypsin, chymotrypsin, and pepsin, at various protease concentrations ([Fig. 6](#F6){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). As expected, a gradual decrease in protease resistance of V~L~s was observed as a function of protease concentration for all three proteases ([Fig. 6A, B, and C](#F6){ref-type="fig"}). At the highest trypsin concentration (20 µg/mL), the protease resistance of V~L~s was in the range of 0--75% with a median resistance of 16% ([Fig. 6A](#F6){ref-type="fig"}). The V~L~s, however, demonstrate higher resistance to chymotrypsin ([Fig. 6B](#F6){ref-type="fig"}). For example, the V~L~s demonstrated a median resistance of 75% at a chymotrypsin concentration of 10 µg/mL compared with 33% for trypsin at the same concentration; at a higher chymotrypsin concentration of 20 µg/mL, V~L~s had a protease resistance range and median of 34--100% and 67.5%, respectively. V~L~s showed the least resistance to pepsin ([Fig. 6C](#F6){ref-type="fig"}). At 1 µg/mL pepsin concentration, two of the V~L~s (HVLP364 and HVLP389) were digested almost completely with 8% and 2% pepsin resistance, respectively, and at 10 µg/mL pepsin concentration, the resistance of all V~L~s decreased to below 34% (median resistance = 1.5%) ([Table 1](#T1){ref-type="table"}). At 20 µg/mL pepsin concentration, the pepsin resistance range and median were 0--23% and 0%, respectively.

![**Figure 6.** GI protease resistance profiles for human V~L~s and V~H~s. (**A**), (**B**), (**C**) Trypsin, chymotrypsin, and pepsin resistance (res.) of human V~L~s (open circles) and their corresponding Cys mutants (closed circles). (**D**) Graph comparing V~L~s to V~H~s in terms of resistance to trypsin, chymotrypsin, and pepsin at 10 µg/mL protease concentrations. Horizontal lines in graphs (**A**)--(**D**) represent medians. (**E**) Graph showing trypsin, chymotrypsin, and pepsin resistance of human V~L~s (open circles) and their corresponding Cys mutants (closed circles) in pair-wise manner at 10 µg/mL protease concentrations (see also [Table 1](#T1){ref-type="table"}). Lines connect protease resistances value for each V~L~ to that for its corresponding mutant version. The*P*values in graphs (**D**) and (**E**) were obtained by the Mann-Whitney test (two-tailed) and Wilcoxon matched-pairs signed rank test (two-tailed), respectively, using GraphPad Prism (GraphPad Software). (**F**) A correlation graph of pepsin resistance *vs. T*~m~ (Pearson's correlation, 0.7807;*P*= 0.0004, r^2^ = 0.6095). Data are from digestion experiments performed at 10 µg/mL pepsin concentrations. Open circles, wild-type V~L~s; closed circles, mutant V~L~s.](mabs-6-219-g6){#F6}

We compared V~L~s to the eight non-aggregating V~H~s in terms of resistance to the three proteases at 10 µg/mL protease concentration ([Fig. 6D](#F6){ref-type="fig"}). We found that there was no significant difference between V~L~s and V~H~s with respect to resistance to trypsin (Mann-Whitney test, two-tailed;*P*= 0.1605). V~L~s were significantly more resistant to chymotrypsin than V~H~s (Mann-Whitney test, two-tailed;*P*= 0.0148), while the opposite was true with respect to resistance to pepsin (Mann-Whitney test, two-tailed;*P*= 0.0011). Theoretical numbers of protease cleavage sites were determined by a protease digestion prediction webware (<http://web.expasy.org/peptide_cutter>). It was found that V~H~s had significantly higher number of protease cleavage sites than V~L~s for all three proteases (trypsin sites medians: 8.5 and 10.5 for V~L~ and V~H~, respectively, \[Mann-Whitney test, two-tailed;*P*= 0.0207\]; chymotrypsin sites medians: 10 and 13.5 for V~L~ and V~H~, respectively, \[Mann-Whitney test, two-tailed;*P*= 0.0070\]; pepsin sites medians: 30 and 39.5 for V~L~ and V~H~, respectively \[Mann-Whitney test, two-tailed;*P*= 0.0002\]).

Disulfide linkage engineering of human V~L~s
--------------------------------------------

To improve the stability of human V~L~s, we created 8 V~L~ mutants (HVLP324S, HVLP325S, HVLP335S, HVLP342S, HVLP351S, HVLP364S, HVLP389S, and HVLP3103S) with a pair of Cys substitutions at amino acid positions 48 and 64 ([Fig. 2A](#F2){ref-type="fig"}). All were expressed well in *E. coli*, albeit with lower yields compared with wild-type V~L~s, with expression yields ranging from 1.1 mg/L of bacterial culture in shaker flasks for HVLP324S to \~11 mg/L for HVLP342S ([Table 1](#T1){ref-type="table"}).

To determine if the engineered Cys pairs formed the desired disulfide linkages in the mutants, mass spectrometry (MS) was performed by analyzing tryptic digests of mutant V~L~s. The MS analyses revealed that the disulfide linkage was formed as intended in all V~L~ mutants ([Fig. S5](#SUP1){ref-type="supplementary-material"}; [Table 2](#T2){ref-type="table"}). The disulfide-linked peptide ions appeared prominent in the survey of LC-MS chromatograms with tryptic peptides of the mutant V~L~s. The expected disulfide-linked peptide sequences corresponding to each mutant V~L~s were confirmed by manual de novo sequencing. When there was only one disulfide linkage between two peptides, the exact disulfide linkage position was confirmed by an almost complete disulfide-linked y fragment ion series from one peptide with the other peptide attached as a modification via a disulfide bond that remains intact under collision-induced dissociation (CID),[@R47]^,^[@R49]^,^[@R56] e.g., the disulfide linked peptides ATLSCR (P1) and GSGTLFTLTISSLEPEDSAVYFCQQR (P2) of HVLP325S ([Table 2](#T2){ref-type="table"}; MS^2^ data not shown). When there were three peptides linked by two disulfide bonds, the y fragment ion containing the linkage close to the N-terminal of two peptides was difficult to observe. Nevertheless, an almost complete y ion series of each peptide was observed. For example, a prominent ion at m/z 1042.66 (6+) from HVLP324S tryptic disulfide-linked peptide LLCFAASTLQSGVPSR (P1), FSCSGSGTDFTLTISNLQPEDFATYYCQQSYSTPR (P2) and VTITCR (P3) was observed from the survey of LC-MS chromatogram ([Fig. S5B](#SUP1){ref-type="supplementary-material"} (top panel);[Table 2](#T2){ref-type="table"}). Informative y fragment ions were observed from P2 with P3 as a modification via a disulfide bond, and an almost complete y ion series of P1 was observed as well ([Fig. S5B](#SUP1){ref-type="supplementary-material"}, top panel). To further confirm the above disulfide bond formation in the mutant HVLP324S, the electron transfer dissociation (ETD)-MS^2^ spectrum of the peptide ion \[M + 5H\]^5+^ at m/z 1250.99 (5+) from the same disulfide-linked peptide of HVLP324S was acquired ([Fig. S5B](#SUP1){ref-type="supplementary-material"}, middle panel). The most abundant charge-reduced ETD fragment ion \[M + 5H\]^4+•^ at m/z 1563.49 (4+) was selected for CID to obtain the ETD-CID-MS^3^ spectrum of the m/z 1250.99 (5+) ion ([Fig. S5B](#SUP1){ref-type="supplementary-material"}, bottom panel). The intact P1, P2, and P3 ions at m/z 691.47 (1+), 1648.86 (1+), and 1956.85 (2+), respectively, were all observed at relatively high abundances upon dissociation of the disulfide linkages of the three linked peptides by ETD. Tryptic peptides linked by the engineered disulfide bonds were positively identified for all mutant V~L~s. These fragments are recorded in [Table 2](#T2){ref-type="table"}.

###### **Table 2.** Disulfide linkage determination of V~L~s by MS analyses

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  V~L~s                                                                                   Tryptic peptides^a^                                                                                             *M*~for~\    *M*~exp~\    Δ*M^c^*\
                                                                                                                                                                                                          (Da)         (Da)         (Da)
  --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------ ------------ ----------
  **HVLP324S**                                                                            VTIT**[C]{.ul}**R\...LL**[C]{.ul}**FAASTLQSGVPSR\...FS**[C]{.ul}**SGSGTDFTLTISNLQPEDFATYY**[C]{.ul}**QQSYSTPR   6249.91^b^   6249.96^b^   -0.05^b^

  **HVLP325S**                                                                            ATLS**[C]{.ul}**R\...GSGTLFTLTISSLEPEDSAVYF**[C]{.ul}**QQR                                                      3495.66      3495.56      0.10

  LL**[C]{.ul}**FDTSNR\...FS**[C]{.ul}**R                                                 1576.71^b^                                                                                                      1576.68^b^   0.03^b^      

  **HVLP335S**                                                                            LL**[C]{.ul}**YGTSNR\...FS**[C]{.ul}**SGSGTHFTLTINR                                                             2750.29^b^   2750.32^b^   -0.03^b^

  ATLS**[C]{.ul}**R\...LEPGDFAVYY**[C]{.ul}**QQYGSSPR                                     2826.27                                                                                                         2826.20      0.07         

  **HVLP342S**                                                                            VTIT**[C]{.ul}**R\...L**[C]{.ul}**YGASSLQGGVPSR\...FS**[C]{.ul}**SGSGTEFTLTI SGLQPEDFATYY**[C]{.ul}**LQHHTYPR   6136.85^b^   6136.80^b^   0.05^b^

  **HVLP351S**                                                                            ATLS**[C]{.ul}**R\...LL**[C]{.ul}**YDASNR\...FS**[C]{.ul}**SGSGTDFTLTISSLEPE DFAVYY**[C]{.ul}**QQR              5049.26^b^   5049.00^b^   0.26^b^

  **HVLP364S**                                                                            LL**[C]{.ul}**YGASSR\...FS**[C]{.ul}**SGSGTDFTLTISR                                                             2644.23^b^   2644.32^b^   -0.09^b^

  ATFS**[C]{.ul}**R\...LEPEDFAVYY**[C]{.ul}**QQYDTSPR                                     3004.29                                                                                                         3004.35      -0.06        

  **HVLP389S**                                                                            LL**[C]{.ul}**YGNDK\...FS**[C]{.ul}**SK                                                                         1492.65^b^   1492.59^b^   0.06^b^

  VTIS**[C]{.ul}**SGSSYNIGENSVSWYQQLPGTAPK...SGTSAT LGITGLQTGDEADYY**[C]{.ul}**GTWDSNLR   6221.84                                                                                                         6221.97      -0.13        

  **HVLP3103S**                                                                           ATLS**[C]{.ul}**R...LL**[C]{.ul}**YGASTR...FS**[C]{.ul}**SGSGTDFTLTISSLQV EDVAVYY**[C]{.ul}**QQYYTTPK           5528.56^b^   5528.52^b^   0.04^b^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Major tryptic peptides containing disulfide linkages are shown, with connecting cysteine residues single or double underlined (native or engineered Cys (C), respectively) and boldfaced (see [Fig. S5](#SUP1){ref-type="supplementary-material"} for experimental details). The triple dots between peptides denote sequence discontinuity, which was caused by the loss of V~L~ sequences after trypsin digestion; the discontinuing peptides, however, are held together by disulfide linkage(s); ^b^The very close match between *M*~for~ (formula molecular mass) and *M*~exp~ (experimental molecular mass) indicates the presence of the Cys48-Cys64 disulfide linkage. ^c^Δ*M* = *M*~for~*- M*~exp~. In addition, the disulfide linkages were confirmed by de novo sequencing the CID or ETD spectra of the disulfide linked peptides (e.g., see [Fig. S5B](#SUP1){ref-type="supplementary-material"}).

Aggregation status of disulfide linkage-engineered human V~L~s
--------------------------------------------------------------

Next, we aimed to determine if the engineered disulfide linkage compromised the non-aggregation status of V~L~s. To this end, we assessed the mutant V~L~s by Superdex 75™ SEC. Except for HVLP364S, which seemingly formed dimeric aggregates at \~17%, the remaining seven V~L~ mutants were monomeric ([Fig. 3A](#F3){ref-type="fig"}), indicating that similar to wild-type V~L~s, mutant V~L~s with the extra disulfide linkage were aggregation-resistant. Moreover, the slight aggregation observed in HVLP325 disappeared in the mutant version, HVLP325S. The *M*~app~s of mutant V~L~s, calculated from their elution volumes, were similar to those of wild-type versions, ranging from 4.9 kDa to 23.5 kDa with a mean *M*~app~ ± SEM of 11.4 ± 2.3 kDa compared with 13.7 ± 2.2 kDa for the wild-type V~L~s. The SEC results were further confirmed by the MALS data, which showed that the V~L~s were indeed monomeric as their experimental *M*~MALS~s were very close to their theoretical *M*~for~s ([Table 1](#T1){ref-type="table"}). Furthermore, the minor HVLP364S peak identified as corresponding to a V~L~ dimer in SEC had indeed the *M*~MALS~ for a dimeric V~L~: 26.21 ± 0.47 kDa (*vs* the expected *M*~for~ of 27.94 kDa).

Probing conformational changes in disulfide linkage-engineered human V~L~s by protein L binding
-----------------------------------------------------------------------------------------------

To probe any possible structural changes brought about by the non-canonical disulfide linkage in V~L~ mutants, the binding of V~L~ mutants to protein L was quantified by SPR. We found that all V~L~ mutants, with the exception of HVLP324S, HVLP342S, and HVLP351S, bound to protein L with almost the same *K*~D~s (and *k*~on~s and *k*~off~s) as their wild-type counterparts ([Fig. S2](#SUP1){ref-type="supplementary-material"}; [Table 1](#T1){ref-type="table"}), indicating that, for the majority of V~L~s, there were no structural changes due to the engineered disulfide linkage, or if there were any, they were too subtle to be sensed by protein L. HVLP324S, HVLP342S and HVLP351S showed 2- to 3-fold affinity increase toward protein L low affinity binding sites compared with wild-type counterparts. In contrast, in all cases the stoichiometry of V~L~:protein L binding remained unchanged between the wild-type and corresponding mutant V~L~s. In the case of HVLP364S, the *K*~D~ seemed to be in the low micromolar range, but a reliable *K*~D~, and consequently a reliable stoichiometry, could not be determined by SPR due to aggregate contamination in the V~L~ sample. A homology structure of HVLP324S suggests that the non-canonical disulfide linkage and protein L binding site occupy distinct locations in mutant V~L~s ([Fig. 7](#F7){ref-type="fig"}). In contrast, for a V~H~ with a similar disulfide linkage mutation, the non-canonical disulfide linkage is very intimate with and imbedded within the protein A binding site ([Fig. 7](#F7){ref-type="fig"}).

![**Figure 7.** Homology structures of HVLP324S V~L~ and huVHAm302S V~H~, comparing the positioning of protein L binding site to protein A binding site relative to the engineered non-canonical disulfide linkages (blue spheres) for the V~L~ and V~H~, respectively. huVHAm302S is a previously described human V~H~ that lost its protein A binding activity by 3.5-fold upon the introduction of a non-canonical disulfide linkage at positions 49 and 69.[@R46] Red spheres represent the native, canonical disulfide linkage, pink- and green-colored regions CDRs and FRs, respectively. Amino acid residues forming protein L binding sites 1 and 2 (top, left panel) and protein A binding site (top, right panel) are shown. The binding site residues were identified based on the published crystal structures of the complex between a human antibody Fab fragment (2A2, κ1 subtype, V~H~3 family) and a single *Peptostreptococcus magnus* protein L domain[@R64] (V~L~) and between Fab 2A2 and domain D of *Staphylococcus aureus* protein A[@R82] (V~H~). Middle and bottom panels show side and top views of the protein L and protein A binding sites in dots and sticks presentations. Protein homology structures were obtained as described in the [Figure 2](#F2){ref-type="fig"} legend. The figures were drawn with PyMOL (<http://www.pymol.org>) and manipulated using Adobe Photoshop CS2 software.](mabs-6-219-g7){#F7}

Thermal stability of disulfide linkage-engineered human V~L~s
-------------------------------------------------------------

To determine the effect of the non-canonical disulfide linkage on the thermal stability of V~L~s, the *T*~m~s of mutant V~L~s were determined and compared with those for wild-type V~L~s. The *T*~m~s were in the range of 63.8--82.5 °C (median *T*~m~ = 72.9°C) compared with 51.9--68.5 °C (median *T*~m~ = 61.9°C) for wild-type V~L~s ([Fig. 4C and D](#F4){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). The thermostability improvements were significant, reflecting a *T*~m~ increase (Δ*T*~m~) range and median of 5.4--17.3 °C and 12.4°C, respectively ([Fig. 4D](#F4){ref-type="fig"}; [Table 1](#T1){ref-type="table"}) (Wilcoxon matched-pairs signed rank test, two-tailed; p = 0.0078). Although the result indicated that the engineered disulfide linkage stabilized the V~L~s regardless of their germline subtypes (κ or λ), the thermostability improvements were more pronounced for the κ3 and λ1 subgroup members compared with the κ1 subgroup members.

GI protease resistance of disulfide linkage-engineered human V~L~s
------------------------------------------------------------------

Previously, V~H~Hs were shown to have acquired protease resistance with the addition of a similar non-canonical disulfide linkage.[@R49] We therefore investigated the effect of the non-canonical disulfide linkage on the resistance of V~L~s to trypsin, chymotrypsin, and pepsin. Mutant V~L~s were digested with varying concentrations of proteases under the same digestion conditions as for wild-type V~L~s ([Fig. 6](#F6){ref-type="fig"}). We observed that there was no significant overall difference between wild-type and mutant V~L~s with respect to resistance to trypsin or chymotrypsin ([Fig. 6A](#F6){ref-type="fig"}, [6B](#F6){ref-type="fig"}, and [6E](#F6){ref-type="fig"}; Wilcoxon matched-pairs signed rank test, two-tailed;*P*= 0.2969, 0.8438, 0.8438, and 1.0625 for trypsin at 1 µg/mL, 5 µg/mL, 10 µg/mL, and 20 µg/mL, respectively;*P*= 0.0625, 0.1563, 0.1484, and 0.0781 for chymotrypsin at 1 µg/mL, 5 µg/mL, 10 µg/mL, and 20 µg/mL, respectively).

Mutant V~L~s, however, showed improved resistance to pepsin. The pepsin resistance medians of wild-type V~L~s were 73% and 1.5% at enzyme concentrations of 1 µg/mL and 10 µg/mL, respectively, and decreased to 0% at the concentration of 20 µg/mL ([Fig. 6C](#F6){ref-type="fig"}). In contrast, mutant V~L~s had pepsin resistance medians of 100%, 54%, 39.5%, and 25.9% at enzyme concentrations of 1, 10, 20, and 50 µg/mL, respectively. The pepsin resistance improvements were significant at 1 and 10 µg/mL enzyme concentrations ([Fig. 6E](#F6){ref-type="fig"}; Wilcoxon matched-pairs signed rank test, two-tailed;*P*= 0.0078 and 0.0156, respectively), but not so at 20 and 50 µg/mL enzyme concentrations (p = 0.0625 for both concentration conditions). Moreover, the correlation between protease resistance and *T*~m~ was explored ([Fig. 6F](#F6){ref-type="fig"}). It was found that in general, V~L~s with higher *T*~m~s had higher resistance to pepsin (Pearson's correlation, 0.6077;*P*= 0.0125, r^2^ = 0.3693, at 1 µg/mL enzyme concentration; Pearson's correlation, 0.7807;*P*= 0.0004, r^2^ = 0.6095, at 10 µg/mL enzyme concentration; Pearson's correlation, 0.7438;*P*= 0.0010, r^2^ = 0.5532, at 20 µg/mL enzyme concentration; Pearson's correlation, 0.6837;*P*= 0.0035, r^2^ = 0.4674, at 50 µg/mL enzyme concentration). No significant correlation was observed in the case of trypsin or chymotrypsin (data not shown).

Discussion
==========

Numerous publications in the past two decades have firmly established the suitability of sdAbs as therapeutic and diagnostic agents. Human V~H~ and V~L~ sdAbs, in particular, have been pursued as therapeutics due to their expected lower immunogenicity in patients compared with other classes of sdAbs such as camelid V~H~Hs and shark V~NAR~s.[@R4]^,^[@R5]^,^[@R32] A number of studies have highlighted V~L~s as bona fide affinity reagents, and a few, in particular, have pointed to an inherent property of V~L~s as being more aggregation resistant than V~H~s.[@R23]^,^[@R32]^-^[@R34]^,^[@R57]^-^[@R61] Thus, from the aggregation point of view, human V~L~s may be preferable over human V~H~s as immunotherapeutics. In this study, we set out to obtain a deeper understanding of V~L~s with respect to a number of biophysical properties, including their aggregation tendencies.

Human V~H~ domains are known for their general tendency to aggregate. Previously, a phage selection method was used to obtain exclusively non-aggregating human V~H~ domains from a naïve human V~H~ phage display library that was propagated as plaques.[@R48] The library, with a size of 6 × 10^8^ transformants, was panned against the B cell super-antigen protein A, and sequencing of more than 110 clones with complete V~H~ open reading frames yielded a total of 15 non-aggregating V~H~s. By applying essentially the same selection approach, we obtained a total of 32 unique sequences out of 34 screened clones from a 200-fold smaller-sized V~L~ library. Given that the selection method has been shown to select only for non-aggregating domains, this high yield isolation of V~L~s implies that human V~L~s are more frequently aggregation resistant than human V~H~s, which is consistent with previous findings.[@R32]^,^[@R33] This is further supported by the fact that our subset of randomly selected protein L binding V~L~s representing different germline origins were indeed non-aggregating as shown by size-exclusion chromatography, hexa-histidine capture SPR and multiangle light scattering experiments. This also confirms the power of the aforementioned selection approach for the isolation of non-aggregating proteins. However, an intrinsic ability of protein L to screen out structurally compromised, aggregating domains in favor of non-aggregating protein L binders during panning experiments is a possibility that may have contributed to the strong selective power of the approach.

It is not surprising that from a library consisting mostly of V~λ~ class V~L~ domains, the vast majority of the protein L binding V~L~s isolated (31 out of 32 unique sequences) were of V~κ~ type (V~κ~3 and V~κ~1 subgroups) with only one being of a V~λ~ type (HVLP389). Previous studies have shown that protein L predominantly binds to the V~κ~ type domains, specifically to those in the subgroups V~κ~1, V~κ~3, and V~κ~4, with a paucity of binding to λ class V~L~s.[@R40]^,^[@R41]^,^[@R62]^-^[@R66] Given the selective nature of our approach for stable (non-aggregating) domains, the predominance of V~κ~3 subgroup type V~L~s (24/31) followed next by V~κ~1 subgroup type V~L~s (7/31), and the absence of any V~κ~4 subgroup type V~L~s, in the pool of selected binders may be a reflection of the relative stability of V~L~s. Previously, it was shown that of the four V~L~ domains representing the consensus sequences of human subgroups V~κ~1--4, the V~κ~3 V~L~ was the most thermodynamically stable followed by the V~κ~1 V~L~, with the V~κ~4 V~L~ appearing to be the least stable of the three.[@R33] Also, unlike the first two V~L~s, which were monomeric, the V~κ~4 V~L~ formed dimers, an indication of its aggregation tendency.[@R33] In fact, a bleak selection for the V~λ~ class V~L~s in this study may not have been just the result of their general lack of binding to protein L, but also the result of their lower stability compared with V~κ~ class V~L~s.[@R33] Consistent with this is the fact that our lone λ class binder belongs to the V~λ~1 subgroup, a subgroup whose one representative was shown to be more thermodynamically stable than two other V~L~s representing subgroups V~λ~2 and V~λ~3. It is also possible, however, that the relative proportion of V~κ~3 and V~κ~1 binders may simply reflect their relative proportions in the original, unselected V~L~ library.

Mutations with respect to V~L~ germline sequences were observed for the pool of selected V~L~s, but, in the absence of mutational studies, it is very difficult to assign solubility roles to mutation positions. Significant mutations at position 96, e.g., mutations from a hydrophobic germline amino acid to a positively-charged amino acid in the vast majority of V~L~s, including 6 of the 8 non-aggregating, representative V~L~s, suggest a solubility role for position 96. Consistent with this, previous studies with immunoglobulin κ1 light chains have suggested that while an aromatic or hydrophobic residue at position 96 enhances dimerization, a charged amino acid (Arg) at the same position results in stable light chain monomers.[@R67] It was explained that Arg-Arg charge repulsion at positions 96 of monomers would interfere with dimer formation.[@R67] Further mutational studies are required to determine if the presence of a positively-charged amino acid at position 96 leads to V~L~s that are more aggregation resistant, and if so, whether a negatively-charged amino acid would have the same effect. Other studies with immunoglobulin V~H~ domains showed that substitution with negatively-charged amino acids, Asp substitution in particular, were more effective than positively-charged substitutions in increasing the aggregation resistance of V~H~s.[@R68]

We also observed that at FR4 positions 105, 106, and 107, instead of the typical Asp/Glu, Ile, and Lys, the majority of the κ class V~L~s had Thr, Val, and Leu, amino acids, respectively, which are characteristic of λ class V~L~s. Whether the substitutions have a role in improving the biophysical properties of the κ class V~L~s remains to be seen. The importance of FR4 residues in improving the aggregation resistance of immunoglobulin variable domains (V~H~Hs and V~H~s) has been suggested.[@R69]^,^[@R70] For example, V~H~Hs, which are known for their high aggregation resistance, have a highly conserved 105Q mutation compared with the aggregation prone V~H~s. Similarly, V~H~s with the 105Q mutation have been shown to have improved aggregation resistance compared with a corresponding wild-type V~H~. Also, the role of J segment, which codes for the FR4 amino acids, in increasing the thermal stability and non-aggregation of V~H~Hs has been shown by others.[@R69]

SPR binding experiments on the eight representative non-aggregating V~L~s confirmed their protein L binding activity. Of interest were the two V~κ~1 type binders, which unlike the V~κ~3 and V~λ~ type V~L~s that bound to protein L with similar micromolar affinities (1--3 µM), bound to protein L with low (0.2 µM and 0.6 µM) and high (0.04 µM and 0.07 µM) affinities. High and low affinity binding of human Fab and light chain of V~κ~1-subgroup type to 2 distinct sites on single Ig binding domains of protein L have been reported previously.[@R63]^,^[@R64] Here a differential V~L~:protein L stoichiometry was also observed, with the λ type V~L~ having a 1:1 binding stoichiometry, the V~κ~3 V~L~s having a 3:1 binding stoichiometry in the majority of cases, and V~κ~1 having a 7:1 binding stoichiometry. Previous SPR binding studies with 5 Ig-binding domains of a protein L showed that while all 5 domains bound to a human V~κ~ light chain of V~κ~1 subgroup, only 3 bound to a human V~κ~ light chain of V~κ~3 subgroup, supporting the higher observed stoichiometry for V~κ~1 binders compared with V~κ~3 binders and the 3:1 stoichiometry found for the V~κ~3 binders. A binding stoichiometry of 7:1 in the case V~κ~1 subgroup binders is plausible, given that our protein L consisted of 4 Ig-binding domains with each Ig-binding domain having up to 2 binding sites that can simultaneously engage with 2 sites on V~κ~1 subgroup binders.[@R63]^,^[@R64]^,^[@R71] A higher affinity and stoichiometry (higher avidity) in the case of V~κ~1 type antibodies should translate to their more sensitive detection by protein L. The low affinity and lack of avidity as a result of a 1:1 stoichiometry, as shown here for the V~λ~ type HVLP389, may be the reason for the reported weak interactions between human Ig λ-light chains and protein L.[@R41]^,^[@R65]^,^[@R66] Thus, failing to detect a V~λ~-protein L interaction should not be interpreted as the lack of protein L binding activity on the part of a V~λ~ type antibody. It should, however, be mentioned that the stoichiometry values are estimates. If the surface is not fully active the theoretical R~max~ for 1:1 binding cannot be attained, resulting in underestimation of the binding stoichiometry. Isothermal titration calorimetry may provide a more accurate means of determining the binding stoichiometries.

Consistent with being highly non-aggregating at concentrations as high as ≈450 μM, the V~L~s showed high reversibility of thermal unfolding at relatively high V~L~ concentrations. In this respect, and with respect to *T*~m~, the V~L~s performed as well as our set of non-aggregating V~H~s. The observed lack of correlation between *T*~m~ and aggregation resistance, expressed in terms of TREs, is consistent with previous findings that showed that aggregation resistant V~H~s may not necessarily have high *T*~m~ or thermodynamic stability.[@R72] Consistent with this finding is the fact that the V~L~ with the highest *T*~m~ from among the eight V~L~s in this study (HVLP325) was also the only one that showed some degree of aggregation.

The V~L~s were different from V~H~s with respect to GI protease resistance patterns. That is, while V~L~s were more resistant to chymotrypsin, the V~H~s were more so to pepsin, with both V~L~s and V~H~s being comparable in terms of resistance to trypsin. The observed protease resistance data for only chymotrypsin could be explained in terms of the number of potential cleavage sites, i.e., V~L~s had a significantly lower number of potential chymotrypsin cleavage sites than V~H~s. Even when only the more protease accessible CDR sequences were considered in the calculation of theoretical number of cleavage sites, the obtained numbers did not fully explain the observed differences between protease resistance profiles of V~L~s and V~H~s (data not shown). Previously for V~H~Hs, increases in pepsin resistance were correlated with increases in *T*~m~s, but this correlation cannot explain the better pepsin resistance of V~H~s here because both V~H~s and V~L~s had very similar *T*~m~s.[@R49] As discussed previously, protease sensitivity is a function of a number of variables including the theoretical number of proteolytic sites, the location of proteolytic sites, and protein compactness and thermodynamic stability.[@R49]^,^[@R73]^,^[@R74]

In an effort to further improve the biophysical properties of V~L~s, we introduced a pair of cysteine residues at amino acid positions 48 and 64, hypothesizing that this would lead to the formation of a disulfide linkage in the sdAb core. Previously, it was shown that the substitution for a pair of cysteine at spatially equivalent positions in V~H~Hs and V~H~s led to the formation of disulfide linkages in all domains tested, with subsequent improvements in thermostability and protease resistance.[@R46]^,^[@R49]^-^[@R52] We too find here that all the V~L~s with the added Cys pair have the intended disulfide linkage, as well as improved thermostability (*T*~m~) and protease resistance. We find that the increases in *T*~m~s (Δ*T*~m~) are relatively high (5.4--17.3 °C, median Δ*T*~m~: 12.4°C) compared with those obtained for a previously reported set of V~H~Hs with similar engineered disulfide linkages (Δ*T*~m~: 4--12°C, median Δ*T*~m~: 7°C).[@R49] This may, at least partly, be due to the fact that *T*~m~s were obtained under different assay conditions and instrument settings. It cannot be excluded, however, that a non-canonical disulfide linkage may have been a better fit to the overall fold of V~L~s, leading to their overall higher Δ*T*~m~ gains.[@R49] This may also explain the differential *T*~m~ gains observed among the mutant V~L~s that were characterized under identical conditions. We also find that the thermostability gain due to the engineered disulfide linkage is more pronounced for the κ3 and λ1 members, compared with the κ1 members; however, general conclusions should await further experiments involving a statistically appropriate sample size.

In terms of protease resistance, the non-canonical disulfide linkage led to increases in pepsin resistance of V~L~s, without compromising their trypsin or chymotrypsin resistance. This is similar to the results obtained with a set of V~H~Hs with similar non-canonical disulfide linkages.[@R49] As with the V~H~Hs, positive correlations between pepsin resistance and *T*~m~ were also observed. The higher pepsin resistance of the mutant V~L~s may be due to the fact that they may have a more compact and thermodynamically stable structure---equating to higher resistance to acid-induced unfolding under pepsin digestion conditions (pH = 2; pepsin is more effective on denatured proteins)---compared with the wild-type V~L~s without the non-canonical disulfide linkage.[@R49] Higher *T*~m~s of mutants, suggesting their higher thermodynamic stabilities, and the fact that V~H~Hs with similar engineered disulfide linkage became resistant to unfolding at pH 2 and 37°C support this speculation.[@R49] Importantly, the introduction of the non-canonical disulfide linkage into V~L~s does not appear to compromise their aggregation resistance. This was shown to be the case for V~H~Hs and V~H~s with similar non-canonical disulfide linkages as well.[@R46]^,^[@R49] In the case of V~H~s, this led to improvements in the aggregation resistance of mutants compared with the wild-type counterparts without the non-canonical disulfide linkage.

The biophysical improvements gained through the introduction of the non-canonical disulfide linkage do come at the expense of expression yield as mutants demonstrated significantly lower expression yields than wild-type V~L~s in *E. coli*. This was also reported in the case of V~H~Hs, which like the V~L~s here, were expressed in *E. coli*.[@R49] Thus, the relatively lower expression yields of Cys mutant domains compared with wild-type ones may have to do with the limited capacity of *E. coli* in folding proteins with higher disulfide linkages such as the Cys mutant V~L~s in this study. This should be resolved by expressing the mutant V~L~s in eukaryotic microorganisms, e.g., yeast or mammalian cells, with the capacity to fold complex proteins such as those with multiple disulfide linkages.

The biophysical improvements also come at the expense of undesirable conformational changes for mutants, which were also reported in the case of V~H~Hs and V~H~s.[@R46]^,^[@R49] The observed differential protease resistance profiles between wild-type and corresponding mutant V~L~s, as well as changes to protein L binding for some of the mutants, support this conclusion. However, for the majority of V~L~s, the conformational changes, as determined by binding measurements of wild-type and Cys mutant V~L~s against protein L, are too subtle to be sensed by protein L, which binds to V~L~s in a conformation-dependent manner.[@R41] This is in sharp contrast to the results obtained with our Cys mutant V~H~s,[@R46] where structural changes as a result of the introduction of non-canonical disulfide linkages were more easily probed with protein A and led to up to 10-fold reductions in protein A binding of mutant V~H~s. Such discrepancy could be due to the fact that, while for V~L~s the protein L binding site is too far from the engineered disulfide linkage to be affected by it, for V~H~s the protein A binding site is in the influencing range of the non-canonical disulfide linkage. This is clearly supported by our homology structure data of a V~L~ and a V~H~ with similar non-canonical disulfide linkages (see [Fig. 7](#F7){ref-type="fig"}). The conformational changes in V~L~ mutants were not reflected in SPR stoichiometry data either, as all wild-type/mutant pairs had the same stoichiometry of binding to protein L.

In conclusion, we demonstrated the suitability of V~L~ sdAbs as affinity reagents, in particular, as immunotherapeutics, and provided insights into the biophysical characteristics of V~L~s. We identified a diversity of non-aggregating V~L~ domains that could form the basis of therapeutics when incorporated as library scaffolds (e.g., into sdAb phage display libraries) as has already been demonstrated.[@R32] As, irrespective of the degree of the stability of the original library scaffold, loop randomization always leads to a proportion of the library consisting of unstable domains, a coupling of affinity selection to stability selection during the panning experiments to filter out unstable binders from the pool of binders is advisable.[@R53]^,^[@R55]^,^[@R72]^,^[@R75] Moreover, we presented a general strategy based on disulfide linkage engineering for stabilizing V~L~s in terms of thermostability and pepsin resistance. The disulfide linkage engineered V~L~s would be the preferred scaffolds for constructing V~L~ phage display libraries over versions without. Such libraries, especially if affinity selected under high temperature conditions, should yield non-aggregating immunotherapeutics that are also thermodynamically stable, like those V~H~ domains that were selected by panning a phage display library under the acidic conditions.[@R72] Due to the positive correlation between pepsin resistance and *T*~m~, affinity selection under heat should yield binders which are also pepsin resistant, hence suitable as oral therapeutics for GI tract applications. The disulfide linkage engineering approach should thus be viewed as an efficacy engineering one for therapeutic V~L~s. The fact that the affinity reagents obtained from the aforementioned V~L~ libraries would have protein L binding properties offers biotechnological advantages similar to those offered by V~H~s that bind to B cell super-antigen protein A.[@R48]

Beyond single domains, the disulfide linkage engineering approach can be applied to domains in the context of scFvs, Fabs, and IgGs. Previously, when a similar disulfide linkage engineering approach was applied to a V~H~ in the context of a Fab, it resulted in a significant increase in the thermostability of the Fab.[@R76] However, the introduction of the disulfide linkage results in conformational changes that may further lead to undesirable affinity and specificity compromises as has been shown in the case of V~H~Hs with similar disulfide linkage engineering.[@R49]^-^[@R51] This should not be a concern with domains that are selected from libraries already containing the non-canonical disulfide linkage.

Materials and Methods
=====================

Human V~L~ library construction and panning
-------------------------------------------

A V~L~ phage display library in a multivalent display format and with plaque formation as the selectable marker was constructed in a similar fashion as a previously described V~H~ phage display library.[@R48] It was anticipated that, as in the case of the V~H~ phage display library, phages displaying non-aggregating domains (V~L~s in the present study) would form larger plaques on bacterial lawns than phages displaying aggregation prone domains, and, as a result, panning the library against super-antigen protein L for several cycles should eventually enrich the library for phage-displayed, aggregation-resistant V~L~s that bind protein L. Such V~L~s can subsequently be retrieved and expressed as soluble, autonomous domains. Briefly, cDNA was synthesized from human spleen mRNA as previously described.[@R48] The cDNA was used as a template for PCR to amplify V~L~ genes in 50 µL reaction volumes using six V~κ~ and 11 V~λ~ back primers[@R77] and four V~κ~ and two V~λ~ forward primers.[@R78] The back and forward primers were modified to have flanking ApaLI and NotI restriction sites, respectively, for subsequent cloning purposes. Forward primers were pooled together in ratios that reflected their degree of degeneracy. V~λ~ genes were subjected to PCR in 11 separate reactions using the pooled V~λ~ forward primers with 11 individual V~λ~ back primers. Similarly, V~κ~ genes were amplified in six separate reactions using the pooled V~κ~ forward primers with six individual V~κ~ back primers. The PCR products were gel-purified and digested with ApaLI and NotI restriction endonucleases, and the library was constructed as previously described.[@R48] PCR was performed on individual library colonies, and the amplified V~L~ genes were sequenced as described before.[@R79] Panning (against protein L; Pierce) and the germline assignment of V~L~s were performed as previously described.[@R48]

Cloning, expression, purification, SEC, and MALS analysis
---------------------------------------------------------

Introduction of cysteine residues at Kabat positions 48 and 64[@R43] of V~L~s was performed using a splice overlap extension method.[@R46] V~L~ expression, purification, concentration determination, and SEC were performed as described for V~H~s.[@R47]^,^[@R55] Size-exclusion chromatograms were normalized as described.[@R46]^,^[@R47] The elution volume values obtained from chromatograms were used to calculate *M*~app~s of V~L~s using the Log *M vs*. *V*~e~ standard curve described in [Figure S1](#SUP1){ref-type="supplementary-material"}. UPLC-SEC-MALS was performed with a Waters BioAcquity system equipped with a Waters PDA detector (Waters). The column temperature was maintained at 30°C with a CM-A column compartment. The samples (10--20 µg) were injected onto a Waters BEH125 SEC column (4.6 mm × 150 mm, 1.7 µm particles) at 0.4 mL/min with PBS (--Ca --Mg, Hyclone Thermo Scientific) as the solvent. MALS data was measured on a Wyatt HELEOS 8+ detector (Wyatt Technology Corporation) and weight average molecular masses (*M*~MALS~s) were calculated using a protein concentration determined using the A~280~ from the PDA detector with extinction coefficients calculated from the amino acid sequences. Experiments were performed in duplicates. MALS data processing was performed with ASTRA 6.1 software (Wyatt Technology Corporation).

Disulfide linkage determination
-------------------------------

Disulfide linkage determination for Cys mutant V~L~s was performed as described elsewhere.[@R46]^,^[@R49] Briefly, tryptic fragments for subsequent MS analysis were prepared as described.[@R47] Purified V~L~s at \~15 pmol/µL in 50% (v/v) acetonitrile + 0.1% (v/v) formic acid were infused at 1 µL/min for electrospray ionization (ESI) mass spectrometric mass measurements of the V~L~s using a Q-TOF 2^TM^ mass spectrometer (Waters). The mass spectra of the V~L~s were de-convoluted using the MaxEnt 1 program in the MassLynx software package (Waters). Aliquots of V~L~ proteolytic digests were re-suspended in 0.1% (v/v) formic acid (aq) and subsequently analyzed by nano-flow reversed-phase HPLC MS (nanoRPLC-ESI-MS) with data-dependent analysis (DDA) using CID on a nanoAcquity UPLC system coupled to a Q-TOF Ultima^TM^ hybrid quadrupole/TOF mass spectrometer (Waters). The peptides were first loaded onto a 180 µm I.D. × 20 mm 5 µm symmetry^®^C18 trap (Waters) and then eluted into a 100 µm I.D. × 10 cm 1.7 µm BEH130C18 column (Waters) using a linear gradient from 0% to 36% solvent B (acetonitrile + 0.1% formic acid) over 36 min followed by 36--90% solvent B for 2 min. Solvent A was 0.1% formic acid in water. The peptide MS^2^ spectra were compared with mutant V~L~ protein sequences using the Mascot™ database searching algorithm (Matrix Science). The MS^2^ spectra of the disulfide-linked peptides were de-convoluted using the MaxEnt 3 program (Waters) for de novo sequencing to confirm and determine the exact disulfide linkage positions. NanoRPLC-ESI-MS analyses with DDA using a combination of ETD and CID were performed on an LTQXL mass spectrometer fitted with an ETD source (Thermo Fisher Scientific) and coupled to a nanoAcquity UPLC system (Waters) using the LC conditions described above. Briefly, for the DDA experiments, the most abundant peptide ion from the survey scan was used for the automatic acquisition of ETD-MS^2^ spectra using 30% normalized collision energy followed by the acquisition of ETD-CID-MS^3^ spectra of the most abundant charge-reduced ions produced by ETD.

SPR binding studies
-------------------

V~L~s were subjected to Superdex 75™ (GE Healthcare) SEC in HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.005% P20 surfactant) at 0.5 mL/min prior to BIACORE analysis and purified monomer peaks were collected even in the absence of any evidence of aggregated material. Binding kinetics for the interaction of V~L~s to protein L were determined by SPR using a BIACORE 3000 biosensor system (GE Healthcare). For wild-type V~L~s, \~600 resonance units (RUs) of protein L or 800 RUs of a Fab reference were immobilized onto research grade CM5 sensorchips (GE Healthcare). For mutant V~L~s, \~650 RUs of protein L (for HVLP324S, HVLP325S, and HVLP342S) or 400 RUs of protein L (for HVLP335S, HVLP351S, HVLP389S, and HVLP3103S) or 400 RUs of ovalbumin (Sigma-Aldrich) as a reference protein were immobilized. For HVLP324S and HVLP342S, \~1,700 RUs of protein L or 2,600 RUs of a ovalbumin reference were immobilized onto research grade CM5 sensorchips to determine binding data for the low affinity binding sites on protein L. Immobilization was performed at protein concentrations of 20 or 50 µg/mL in 10 mM acetate buffer, pH 4.5, using an amine coupling kit supplied by the manufacturer (GE Healthcare). All measurements were performed at 25°C in HBS-EP buffer at 40 or 50 µL/min. The surfaces were regenerated through washing with the running buffer. Data were evaluated using BIAevaluation 4.1 software (GE Healthcare). The stoichiometry of binding (V~L~:protein L) was estimated by comparing the observed R~max~s and theoretical R~max~s for 1:1 binding.

SPR analysis for the binding of V~L~s, a control llama V~H~H monomer (A4.2), and a control V~H~ homodimer to a Ni^2+^-NTA sensorchip was performed as described previously.[@R46] All V~L~/V~H~/V~H~H domains had His~6~ tags at their C-termini and the protein preparations lacked contaminating species without the His~6~ tag as determined by Western blot and SDS-PAGE analyses. The V~H~ homodimer is formed by the non-covalent association of two V~H~ monomer units, and, as a result, has two C-terminal His~6~ tags. SPR experiments were performed with protein fractions corresponding to the dimeric peak in the case of the V~H~ dimer control and monomeric peaks for the remaining V~L~/V~H~H domains. RUs from duplicate data sets were averaged and then normalized to obtain %RU. The SPR binding of antibody domains to an activated NTA sensorchip was determined at 25°C using a BIACORE 3000. In each cycle, NiCl~2~ was injected, followed by an injection of V~L~/V~H~/V~H~H. Sensorgrams were run in duplicates. The NTA chip was regenerated with EDTA before the next cycle. Dissociation rate constants (*k*~off~s) were obtained over 60 s periods between 315--375 s and 780--840 s and data were analyzed with BIAevaluation 4.1 software.

Protease digestion experiments
------------------------------

Digestion experiments were performed in a total volume of 30 µL with 6 µg of V~L~ in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na~2~HPO~4~, 1.47 mM KH~2~PO~4~, pH 7.4) at 37°C for 1 h with an enzyme to V~L~ ratio of 1:200, 1:40, 1:20, and 1:10 (trypsin/chymotrypsin), corresponding to 1 µg/mL, 5 µg/mL, 10 µg/mL, and 20 µg/mL protease concentrations, respectively, or 1:200, 1:20, 1:10, and 1:4 (pepsin), which corresponds to 1 µg/mL, 10 µg/mL, 20 µg/mL, and 50 µg/mL protease concentrations, respectively. Tryptic and chymotryptic digestion experiments were performed using sequencing grade enzymes (Roche Diagnostics) according to the manufacturer's instructions. Peptic digestion experiments were performed at pH 2.0 using pepsin from Sigma-Aldrich. In control experiments, enzymes were replaced with equal volumes of reaction buffers. Reactions were stopped by adding an equal volume of SDS-PAGE sample buffer containing 0.2 M dithiothreitol and boiling mixtures at 95°C for 5 min. The samples were then subjected to SDS-PAGE analysis and the percentages of intact sdAbs after protease digestions were determined by spot density analysis as described.[@R49] For V~H~s, digestion experiments were performed as described for V~L~s with an enzyme to V~H~ ratio of 1:20.

TRE experiments
---------------

TREs were determined by SPR as previously described.[@R48] Briefly, V~L~s or V~H~s were incubated at 85°C for 20 min at concentrations of 4 or 20 µM, slowly cooled to room temperature for 30 min, centrifuged at 16,000 X *g* for 5 min at 22°C, and the supernatants, termed "refolded," were kept for subsequent SPR analysis. Following this, binding analysis against protein L and protein A for V~L~s and V~H~s, respectively, was performed. Native and refolded domains were analyzed under identical conditions. For V~L~s at 4 µM, 600 RUs of protein L and 700 RUs of a Fab reference were immobilized at 25 or 50 µg/mL in 10 mM acetate buffer, pH 4.5. For V~H~s at 4 µM, 600 RUs of protein A (Sigma-Aldrich) or ovalbumin reference were immobilized at 50 µg/mL in 10 mM acetate buffer, pH 4.5. For V~L~s at 20 µM, 2,100 RUs of protein L and 1,200 RUs of ovalbumin reference were immobilized at 100 µg/mL in acetate buffer, pH 4.0, and 50 µg/mL in 10 mM acetate buffer, pH 4.5, respectively. For V~H~s at 20 µM, 650--1,100 RUs of protein A and 600--1,200 RUs of ovalbumin were immobilized at 50 µg/mL in 10 mM acetate buffer, pH 4.5. In all instances, the analyses were performed at 25°C in HBS-EP buffer at 40 µL/min. The surfaces were washed thoroughly with the running buffer for regeneration. Data were analyzed with BIAevaluation 4.1 software and *K*~D~s were analyzed with 1:1 binding models. Refolding efficiencies were expressed in terms of the ratio of *K*~D~ (refolded)/*K*~D~ (native).[@R48]

*T*~m~ measurements
-------------------

Circular dichroism spectra and *T*~m~s of V~L~s and V~H~s were obtained as described previously[@R47]^,^[@R49] using a Jasco J-815 spectropolarimeter (Jasco) equipped with a Peltier thermoelectric type temperature control system. The circular dichroism spectra were recorded over a temperature range of 30°C to 96°C in 100 mM sodium phosphate buffer, pH 7.4, and with a protein concentration of 50 µg/mL. Ellipticity changes at 203 nm for HVLP325 and HVLP389, at 218 nm for HVLP324, HVLP335, HVLP342, HVLP351, HVLP364, and HVLP3103, at 210 nm for Cys mutant V~L~s, at 205 nm for HVHP421, HVHP428, and HVHP429, at 200 nm for HVHP413, HVHP419, and HVHP420, and at 202 nm for HVHP44 and HVHP414 were used for constructing thermal unfolding curves and subsequent calculations of *T*~m~s. At these wavelengths, wide differences in ellipticity values between the folded (at 30°C) and fully denatured (at 90°C) domains allowed reliable determination of *T*~m~s ([Fig. S6](#SUP1){ref-type="supplementary-material"}).
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CDR

:   complementarity-determining region

CID

:   collision induced dissociation

DDA

:   data dependent analysis

ETD

:   electron transfer dissociation

Fab

:   fragment antigen-binding
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HBS-EP buffer

:   10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.005% P20 surfactant

GI

:   gastrointestinal

*K*~D~

:   equilibrium dissociation constant

MALS

:   multiangle light scattering

*M*~app~

:   apparent molecular mass

*M*~for~

:   formula molecular mass

*M*~MALS~

:   molecular mass determined by MALS

MS

:   mass spectrometry

RU

:   resonance unit

sdAb

:   single-domain antibody

SEC

:   size-exclusion chromatography

scFv

:   single chain Fv fragment of an antibody

SPR

:   surface plasmon resonance

*T*~m~

:   melting temperature

TRE

:   thermal refolding efficiency

V~H~

:   antibody heavy chain variable domain

V~H~H

:   camelid heavy chain antibody variable domain

V~L~

:   antibody light chain variable domain

V~NAR~

:   shark IgNAR (Ig New Antigen Receptor) variable domain
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